Clinical Trial

a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia

Study acronym: phase Ib/Ⅱa st
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 30, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the safety and tolerability of multiple subcutaneous injections of JMT202 injection in Chinese participants with hypertriglyceridemia
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-22; most recent amendment 2025-12-22.
Status change: Not Yet Recruiting → Recruiting 2025-12-22
Trial Details
NCT Number NCT07140809
Lead Sponsor Shanghai JMT-Bio Inc.
Conditions Hypertriglyceridemia
Enrollment 48 participants
Start Date 2025-09-09
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-30